Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.38B 3.83B 3.54B 3.26B 6.14B 422B 6.28B 42.25B 16.62B 207B 16.46B 16.1B 712B P/E 2026 *
66.6x
P/E 2027 * 34.8x
Enterprise Value 3.42B 2.99B 2.76B 2.54B 4.79B 329B 4.9B 32.96B 12.96B 161B 12.84B 12.56B 555B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.3x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -
1 day-0.12%
1 week-2.36%
Current month+1.19%
1 month+18.41%
3 months+15.47%
6 months-1.50%
Current year-4.16%
1 week 24.95
Extreme 24.95
26.23
1 month 21.59
Extreme 21.59
27.31
Current year 19.89
Extreme 19.89
27.81
1 year 19.69
Extreme 19.69
28.35
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Sell

Controller/Auditor

-11,421 0.0067%
29/05/26
Baker Bros. Advisors LP
FreeCompany 101,260 0.0591%
29/05/26 Fiscal year

Director

41,529 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%-2.36%+13.48%-22.40% 4.38B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
-0.08%-3.01%+1,282.83%+635.80% 11.76B
Average +0.16%-0.20%+202.72%+155.31% 21.06B
Weighted average by Cap. +0.23%+0.30%+170.94%+181.45%

Financials

2026 *2027 *
Net sales 1.24B 1.08B 1B 922M 1.74B 119B 1.78B 11.96B 4.7B 58.52B 4.66B 4.56B 201B 1.4B 1.22B 1.13B 1.04B 1.95B 134B 2B 13.45B 5.29B 65.81B 5.24B 5.12B 227B
Net income 65.75M 57.46M 53.02M 48.87M 92.12M 6.33B 94.16M 634M 249M 3.1B 247M 242M 10.68B 134M 117M 108M 99.42M 187M 12.88B 192M 1.29B 507M 6.31B 502M 491M 21.72B
Net Debt -965M -843M -778M -717M -1.35B -92.89B -1.38B -9.3B -3.66B -45.49B -3.62B -3.54B -157B -1.18B -1.03B -949M -875M -1.65B -113B -1.69B -11.35B -4.46B -55.52B -4.42B -4.32B -191B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
17/07/26 US$25.60 -0.12% 1,207,375
16/07/26 US$25.63 -1.12% 2,189,326
15/07/26 US$25.92 +1.69% 1,274,099
14/07/26 US$25.49 -0.04% 1,221,006
13/07/26 US$25.50 -2.75% 1,562,833
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
25.60USD
Average target price
32.65USD
Spread / Average Target
+27.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock